
-
6x the Efficacy vs VehicleIn two 12-week pivotal studies, the Physician Global Assessment (PGA) success† rate was 36% and 40% for patients using VTAMA cream vs 6% and 6% for patients on vehicle.1
-
Favorable Safety and TolerabilityIn clinical studies, VTAMA cream showed a favorable and consistent safety profile and was well tolerated, even on sensitive areas of skin.4-6
-
~4 Month Off-Treatment EffectIn an open-label, long-term extension study, the median time to first disease worsening (defined as PGA≥2 [mild]) was 114 days (95% CI: 85, 142).1
†PGA success: PGA score of 0 or 1 and ≥2-grade improvement from baseline at week 12.
what patients from clinical studies
said about VTAMA cream
said about VTAMA cream



What would you like to see next?